Our study demonstrated combinatorial benefits of amivantamab and pembrolizumab by effectively remodeling the tumor-immune microenvironment, providing a strong preclinical rationale to clinically combine amivantamab and PD-1 blockade treatment. This evidence concerns the gene PDCD1 and neoplasm.